hrp0082p2-d2-552 | Puberty and Neuroendocrinology (1) | ESPE2014

Pubertal Development in a Cohort of Romanian School-Aged Children

Pascanu Ionela , Capraru Oana , Cota Ancuta , Pop Raluca

Background: The average age of onset of puberty development has lowered in last decades due to multiple confounding factors. No recent populational studies are available in our country regarding pubertal development.Objective and hypotheses: The aim of our study was to identify the timing of pubertal characteristics in our region in children of school age. Our hypothesis was that the age of pubertal onset has diminished.Method: Typ...

hrp0089p2-p287 | Multisystem Endocrine Disorders P2 | ESPE2018

Endocrine Challenges in Patients with Thalassemia

Haamberg Tanja Christa , Schneider Christine , Rossler Jochen , Fluck Christa E

Introduction: Beta-thalassaemia is caused by point mutations leading to decreased production of beta-globin, which results in defective red blood cells and ineffective erythropoiesis. Complications are microcytic hypochromic anaemia, extramedullary haematopoiesis and increased intestinal iron absorption due to compensation mechanisms. The resulting iron overload can be aggravated by recurrent blood transfusions necessary for treatment of anaemia and may cause several endocrine...

hrp0086p2-p49 | Adrenal P2 | ESPE2016

Evaluation of the Combination of Anti-androgen and Anti-estrogen Treatment in Classical Congenital Adrenal Hyperplasia in Boys: Retrospective Study of 11 Cases

Lefevre Christine , Weill Jacques , Mazoyer Harmony , Cartigny Maryse

Background: Final height (FH) is reduced in congenital adrenal hyperplasia (CAH), due both to overtreatment by hydrocortisone therapy and to advanced epiphyseal closure linked to hyperandrogenism by Hydrocortisone therapeutic insufficiency.Objective and hypotheses: To evaluate the efficacy and safety of the addition of an androgen receptor competitor and an aromatase inhibitor to reduced hydrocortisone doses.Method...

hrp0086p1-p120 | Bone & Mineral Metabolism P1 | ESPE2016

Practicalities of Bisphosphonate use in UK Paediatric Tertiary Centres

Price Victoria , Ramakrishnan Renuka , Burren Christine , Dharmaraj Poonam

Background: On reviewing practical aspects of intravenous bisphosphonate use in our tertiary Children’s Hospital, we noted disparity between departments who prescribed these drugs. This included issues pertinent to patient safety and hospital management, e.g. the need for overnight admission for the first infusion, blood tests and monitoring for adverse events (AEs). We therefore decided to survey the practices of other tertiary Paediatric Endocrinology Centres.<p cla...

hrp0086p2-p173 | Bone &amp; Mineral Metabolism P2 | ESPE2016

Bartter Syndrome with Bone-Destroying Hyperparathyroidism: About Two Cases, Genetically Proved, with Long-Lasting Follow-Up

Novo Robert , Cartigny Maryse , Lefevre Christine , Weill Jacques

Background: Bartter syndrome represents a rare severe condition, autosomal recessive, corresponding to several genes, characterized by an illness of the renal ascending branch of the handle of Henle. Only 15 cases of BSHPT have been communicated, either in publications or orally, but none presented such severe bone manifestation as ours.Objective and hypotheses: To present bone features of two patients suffering from severe BHSPT, so as the therapeutic a...

hrp0086p1-p193 | Diabetes P1 | ESPE2016

Recombinant Human Insulin-Like Growth Factor 1 (rh IGF1) Treatment of a Case of Leprechaunism: A Two and a Half Year Follow-Up

Valle Aline , Lefevre Christine , Weill Jacques , Cartigny Maryse

Background: Leprechaunism, due to a mutation of both alleles of insulin receptor gene, is a most severe and precociously life-threatening condition, difficult to treat.Objective and hypotheses: In leprechaunism rhIGF1 may replace insulin through I the insulin-like metabolic properties of its own receptor.Method: rh IGF1 was continuously subcutaneously administered through a.pump from the age of four months and adjusted according to...

hrp0086p2-p653 | Growth P2 | ESPE2016

Improving the ‘Gold Standard’: The Insulin Tolerance Test Revisited

Daskas Nikolaos , Barton John , Burren Christine , Crowne Elizabeth

Background: The optimal method to assess GH status remains controversial. GH provocation tests are used and the Insulin Tolerance Test (ITT) is regarded as the ‘gold standard’ to diagnose GH deficiency (GHD). The original selection of 0, 20, 30, 60, 90 and 120 min time points is still used in many protocols worldwide, but variations have evolved.Objective and hypotheses: Comparing standard ITT (StdITT) to a revised (RevITT) protocol.<p clas...

hrp0084p2-271 | Diabetes | ESPE2015

Evaluation of a Novel Tool to Adjust Insulin Boluses Based on Continuous Glucose Monitoring Trend Arrows and Insulin Sensitivity (Trend Arrow Adjustment Tool©) in Children and Youth with Type 1 Diabetes Using Insulin Pump Therapy

Heffernan Emmeline , Lawson Margaret , Bradley Brenda , Courtney Jennilea , Richardson Christine

Background: Continuous glucose monitoring (CGM) measures interstitial glucose and displays trend arrows, showing the direction and rate of change in glucose. Trend arrows allow the child/youth to take action to prevent hyper- and hypoglycaemia. Effective strategies for adjusting insulin for trend arrows are lacking. The JDRF CGM Study Group recommended a 10–20% increase/decrease in the insulin dose. However, the bolus dose is dependent on amount of food to be consumed and...

hrp0089p1-p159 | Growth &amp; Syndromes P1 | ESPE2018

Does X-Chromosome Gene Dosage Determine Growth and Phenotypic Features in Turner Syndrome with 45,X/46,XX Mosaicism on Standard Karyotyping? A Cross-Sectional Analysis of the French National Rare Disease Network Database

Fiot Elodie , Zenaty Delphine , Pick Paul , Boizeau Patricia , Haignere Jeremy , Dos Santos Sophie , Christin-Maitre Sophie , Carel Jean-Claude , Leger Juliane , Turner Syndrome Study Group French

Background: Turner Syndrome (TS) with a 45,X phenotype is generally more severe than TS with mosaicism, but the potential role of the degree of mosaicism in modulating TS phenotype has never been investigated. We assessed the impact of various degrees of 45,X/ 46,XX mosaicism on phenotypic features in a cohort of TS patients.Method: We analysed a cohort of TS with 45,X/ 46,XX mosaicism (percentage mosaicism from peripheral blood lymphocytes, known in <em...

hrp0095fc9.4 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Delayed puberty: unraveling the different trajectories and contributions of AI

Antoniou Maria-Christina , Xu Cheng , Zouaghi Yassine , Papadakis Georgios , Stoppa-Vaucher Sophie , Kolesinska Zofia , Bouthors Thérèse , Lore Ruiz Arana Inge , Elowe-Gruau Eglantine , Phan-Hug Franziska , Pasquier Jerôme , Adamo Michela , Deladoey Johnny , Vuissoz Jean-Marc , Busiah Kanetee , Hauschild Michael , Santoni Federico , Acierno James , Pitteloud Nelly

Introduction: Differentiation between constitutional delay of growth and puberty (CDGP) and congenital hypogonadotropic hypogonadism (CHH) during early adolescence is challenging, as patients exhibit a similar clinical picture and there are no definite clinical or biochemical markers that distinguish these 2 pathologies. A delay in diagnosis, especially for CHH, may have short and long-term health consequences. The aims of this study were: 1) To evaluate the u...